Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

N/A(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07235345Not ApplicableEnrolling By Invitation

To Investigate the Effect of Pulmonary Surfactant With Different Inspired Oxygen Concentrations on the Clinical Outcomes of Very Preterm Infants Under Non-invasive Assisted Ventilation

Role: collaborator

NCT05965193Phase 3Recruiting

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke：Longterm Outcome (OPENS-3L)

Role: collaborator

NCT05965687Phase 3Recruiting

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)

Role: collaborator

NCT04681651Phase 2Completed

Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)

Role: collaborator

NCT03406832Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Role: collaborator

NCT03406819Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Role: collaborator

NCT01614548Completed

Management of Prostate Cancer in Central China

Role: collaborator

All 7 trials loaded